Tocainide

Drug Levels and Effects:




Summary of Use during Lactation:


Limited data indicate that rather large amounts of tocainide are excreted into breastmilk. Because of the relative lack of data concerning breastfeeding during maternal tocainide therapy, exclusively breastfed infants should be carefully monitored if this drug is used during lactation, possibly including measurement of serum levels to rule out toxicity if there is a concern.


Drug Levels:


Maternal Levels.

One woman taking tocainide 400 mg every 8 hours orally during the early postpartum period had levels of 12 mg/L at 0.5 hour before a dose and 28 mg/L at 2 hours after a dose.[1] These data indicate that an exclusively breastfed infant would receive between 9 and 21% of the maternal weight-adjusted dosage.

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


Relevant published information was not found as of the revision date.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


References:


1. Wilson JH. Breast milk tocainide levels. J Cardiovasc Pharmacol. 1988;12:497. Letter. PMID:2465453



Substance Identification:




Substance Name:

Tocainide

CAS Registry Number:

41708-72-9

Drug Class:


  • Antiarrhythmics


  • Administrative Information:




    LactMed Record Number:


    260


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.